Patients and caregivers? core aspirations to maximize the attractiveness of ASPIRE - a phase 2b trial to investigate the disease modifying potential of buloxibutid in IPF - Vienna 2024

Pulmonary fibrosis and all of its clinical aspects

Chair(s): Athina Trachalaki, Diego Castillo Villegas

Session type: Poster session

Patients and caregivers? core aspirations to maximize the attractiveness of ASPIRE - a phase 2b trial to investigate the disease modifying potential of buloxibutid in IPF

Asa Magnusson

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Investigation of the gut microbiata profiles of patients with idiopathic pulmonary fibrosis

Baykal T?lek

Poster

Abstract

Patients and caregivers core aspirations to maximize the attractiveness of ASPIRE - a phase 2b trial to investigate the disease modifying potential of buloxibutid in IPF

Asa Magnusson

Poster

Abstract

Cognitive Function Status and Clinical Effects in Fibrotic Interstitial Lung Diseases

Elif Yelda Ozgun Niksarlioglu

Poster

Abstract

Diagnostic and prognostic trajectories of ILDs after the MDD

Francesco Amati

Poster

Abstract

Acute exacerbations of interstitial lung diseases (AE-ILD): impact of an emergency action protocol

Juan Pablo Orozco Zapata

Poster

Abstract

Sex-specific aspects in an unclassified population of patients with interstitial lung disease (ILD) undergoing transbronchial cryobiopsy (TCB)

Franziska Trudzinski

Abstract

Radiological and histopathological features of Early Idiopathic Pulmunary Fibrosis (Early IPF)

Martina Maria Marinato

Poster

Abstract

Bronchial artery hypertrophy is common in lung fibrosis and associated with mutations of telomere-related genes

Poster

Abstract

Thyroid and thorax: prevalence and correlates of interstitial lung abnormalities in hypothyroidism

Akhlesh Rajpoot

Poster

Abstract

Identifying outcome domains to establish a core outcome set for progressive pulmonary fibrosis: a scoping review.

Zehra Nur Toreyin

Poster

Abstract

The impact of immortal time bias on the estimated mortality benefit of antifibrotic therapy in IPF

Marit Bj?rn Wilskow

Poster

Abstract

Prevalence and clinical impacts of coronary artery disease in patients with interstitial lung disease

Hyun Seok Kwak

Poster

Abstract

Prevention of progression in early fibrosing interstitial lung disease patients: Using economic modelling to inform evidence generation.

Michael Baldwin

Poster

Abstract

Clinical manifestations and prognosis of IPF patients with simple honeycomb wall thickening: A Case Series.

Ting Yang

Poster

Abstract

Frequency of lung cancer in idiopathic pulmonary fibrosis

Zuleyha Bingol

Poster

Abstract

Pre-surgical clinico-radiologic-pathological risks for post-surgical acute exacerbation of interstitial pneumonia in resectable lung cancer patients

Atsushi Miyamoto

Poster

Abstract

The density histogram-derived computerized integrated index (CII) is a mortality predictor in patients with idiopathic pulmonary fibrosis

Paola Rebecca Iovine

Poster

Abstract

Healthcare utilization in the diagnostics of interstitial lung disease

Thomas Skovhus Prior

Poster

Abstract

Deleterious impact of trivial to severe pulmonary fibrosis and emphysema on mortality and acute lung injury in patients with lung cancer

Yutaka Tomishima

Poster

Abstract

A benefit-analysis review of patients with IPF/CPFE attending an ERN-ILD specialist centre over 10 years.

Paul Bergin

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}